4.
Group | Rash (%) | Diarrhea (%) | Liver damage (%) | |
Gefitinib | All | 31 (62.3%) | 12 (24.5%) | 13 (26.5%) |
Grade 3-4 | 6 (12.2%) | 1 (2.0%) | 2 (4.0%) | |
Erlotinib | All | 16 (94.1%) | 12 (70.6%) | 2 (11.7%) |
Grade 3-4 | 6 (35.3%) | 3 (17.6%) | 0 (0) | |
P | All | 0.002 | 0.004 | 0.318 |
Grade 3-4 | 0.022 | 0.069 | ||
Total | 47 (71.2%) | 24 (36.4%) | 15 (22.7%) |